Codiak Biosciences

Codiak Biosciences

Founded 2015 Post-IPO Equity Total: $257.40M Biotechnology, Health and Wellness

Codiak Biosciences is a biotechnology startup that was founded in 2015. The company is focused on developing exosome-based therapeutics, which constitute a new class of medicines with the potential to address a wide spectrum of diseases with high unmet medical need. Codiak leverages the biology of exosomes as natural intercellular transfer mechanisms and has created its proprietary engEx Platform to enhance the innate properties of exosomes. This platform enables the design, engineering, and manufacture of novel exosome therapeutic candidates. Codiak has built a robust pipeline of engineered exosomes aimed at treating a broad range of disease areas, including oncology, neuro-oncology, neurology, neuromuscular disease, and infectious disease. The startup has recently secured a significant $20.00MPost-IPO Equity investment on 12 September 2022. This funding is indicative of the growing interest in the potential of exosome-based therapeutics and bodes well for Codiak's future development and product commercialization efforts. As Codiak continues to advance its innovative therapies, it positions itself as a promising player in advancing treatments for various challenging diseases within the biopharmaceutical industry.

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Equity	$20.00M	-		12 Sep 2022
Post IPO Equity	$2.50M	1	Coalition for Epidemic Preparedness Innovations	05 Jul 2022
Post IPO Equity	$66.40M	-		11 Feb 2021
Series C	$76.50M	10	Arch Venture Partners, Casdin Capital +8	29 Nov 2017
Series B	$61.00M	6	Arch Venture Partners, Flagship Pioneering +4	26 Jan 2016
Series A	$31.00M	3	Arch Venture Partners, Flagship Pioneering +1	17 Nov 2015

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Equity

$20.00M

12 Sep 2022

Post IPO Equity

$2.50M

Coalition for Epidemic Preparedness Innovations

05 Jul 2022

Post IPO Equity

$66.40M

11 Feb 2021

Series C

$76.50M

Arch Venture Partners, Casdin Capital +8

29 Nov 2017

Series B

$61.00M

Arch Venture Partners, Flagship Pioneering +4

26 Jan 2016

Series A

$31.00M

Arch Venture Partners, Flagship Pioneering +1

17 Nov 2015

FAQ About Codiak Biosciences

Codiak is a clinical-stage biopharmaceutical company focused on developing exosome-based therapeutics, a new class of medicines with the potential to address a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms,...

Codiak Biosciences was founded in 2015.

Codiak Biosciences operates in Biotechnology and Health and Wellness.

Codiak Biosciences has completed 6 funding rounds, raising a total of $257.40M. The latest funding stage is Post-IPO Equity.

Top alternatives and competitors to Codiak Biosciences include Visterra Inc., Fate Therapeutics Inc., MediciNova, Attovia Therapeutics, Goldfinch Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Codiak Biosciences and Visterra Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Codiak Biosciences

Funding Rounds & Investors (6)

Codiak Biosciences Alternatives & Competitors

FAQ About Codiak Biosciences